Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis.

Brain M Grey matter atrophy Multiple sclerosis β-amyloid

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 09 08 2019
revised: 13 12 2019
accepted: 18 12 2019
medline: 31 12 2019
pubmed: 31 12 2019
entrez: 30 12 2019
Statut: ppublish

Résumé

Grey matter (GM) atrophy is present from the earliest stages of multiple sclerosis (MS) and occurs largely in a nonrandom manner. However, the biological mechanisms underlying the progression of regional atrophy are still unclear. Aim of this study is to investigate whether amyloid pathology might be involved in determining the pattern of GM atrophy over time. Forty-six subjects were recruited: 31 newly diagnosed relapsing-remitting (RR-) MS patients and 15 age- and sex-matched healthy controls (HC). Aβ levels were determined in CSF samples from all subjects. All participants underwent brain magnetic resonance imaging (MRI) at baseline, and 23 out of 31 patients at one year follow-up. T1-weighted scans were segmented using the Geodesic Information Flows software. Non-parametric statistical tests were used for between-group comparisons and multiple regression analyses. CSF Aβ concentration was the best predictor of global GM loss over time after age (β = 0.403; p = 0.024), in particular in the left precuneus (p = 0.045), in the left middle cingulate gyrus (p = 0.009), in the left precentral gyrus (p = 0.021) and in the right angular gyrus (p = 0.029). CSF Aβ levels seem to be crucial in MS early brain volume loss as GM atrophy manifests in regions particularly vulnerable to early Aβ deposition.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Grey matter (GM) atrophy is present from the earliest stages of multiple sclerosis (MS) and occurs largely in a nonrandom manner. However, the biological mechanisms underlying the progression of regional atrophy are still unclear. Aim of this study is to investigate whether amyloid pathology might be involved in determining the pattern of GM atrophy over time.
METHODS METHODS
Forty-six subjects were recruited: 31 newly diagnosed relapsing-remitting (RR-) MS patients and 15 age- and sex-matched healthy controls (HC). Aβ levels were determined in CSF samples from all subjects. All participants underwent brain magnetic resonance imaging (MRI) at baseline, and 23 out of 31 patients at one year follow-up. T1-weighted scans were segmented using the Geodesic Information Flows software. Non-parametric statistical tests were used for between-group comparisons and multiple regression analyses.
RESULTS RESULTS
CSF Aβ concentration was the best predictor of global GM loss over time after age (β = 0.403; p = 0.024), in particular in the left precuneus (p = 0.045), in the left middle cingulate gyrus (p = 0.009), in the left precentral gyrus (p = 0.021) and in the right angular gyrus (p = 0.029).
CONCLUSIONS CONCLUSIONS
CSF Aβ levels seem to be crucial in MS early brain volume loss as GM atrophy manifests in regions particularly vulnerable to early Aβ deposition.

Identifiants

pubmed: 31884385
pii: S2211-0348(19)30970-8
doi: 10.1016/j.msard.2019.101899
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101899

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Auteurs

Anna M Pietroboni (AM)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy. Electronic address: pb.anna@libero.it.

Annalisa Colombi (A)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Tiziana Carandini (T)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Valeria E Contarino (VE)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Laura Ghezzi (L)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Giorgio G Fumagalli (GG)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.

Andrea Arighi (A)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Chiara Fenoglio (C)

Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Milena A De Riz (MA)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Fabio Triulzi (F)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; University of Milan, Milan, Italy.

Elio Scarpini (E)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Daniela Galimberti (D)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Dino Ferrari Center, Milan, Italy; University of Milan, Milan, Italy.

Classifications MeSH